Announced
Completed
Synopsis
Sensei Biotherapeutics, a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, completed the acquisition of Alvaxa Biosciences, a camelid antibody therapeutics company. Financial terms were not disclosed. “We are delighted to announce the acquisition of Alvaxa Biosciences. Nanobodies are the next stage of our strategy to build out our proprietary ImmunoPhage™ platform, a next-generation universal vaccine platform capable of driving precise antigen-specific immunity while also amplifying or attenuating key immune signals, all within a vaccine,” John Celebi, Sensei Biotherapeutics President and CEO.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.